In patients with symptomatic stable angina and CAD, Adalat® (nifedipine GITS) significantly reduces the need for medical and procedural interventions, thereby limiting the potential burden on healthcare resources.
Background
- The financial burden of cardiovascular disease (CVD) management is an increasingly important consideration for healthcare providers.
- ACTION provided a unique opportunity to look at the benefits of treatment with Adalat® in terms of healthcare resource consumption, with data from a very large patient population.
Main Results
Compared with placebo, Adalat® was associated with:
- 28% reduction in the incidence of any stroke or transient ischaemic attack (TIA)
- 29% reduction in the incidence of new overt heart failure
- 21% reduction in the need for coronary artery bypass graft
- 18% reduction in the need for angiography.
Compared with placebo, Adalat® was associated with a reduction in the use of other blood-pressure (BP)-lowering drugs, including:
- Angiotensin-converting enzyme (ACE) inhibitors (23% vs 27%)
- Angiotensin receptor blockers (ARBs) (4.3% vs 7.0%)
- Diuretics (18% vs 20%)
- Cardiac glycosides (1.4% vs 2.1%).
Main Conclusion
Compared with placebo, Adalat® reduced the need for additional medical and surgical intervention in patients with CAD who were already receiving best practice therapy – this may result in cost-savings to the healthcare system.